Identifier to cite or link to this item: http://hdl.handle.net/20.500.13003/11830
Demographic and clinical profile of idiopathic pulmonary fibrosis patients in Spain: the SEPAR National Registry
Identifiers
ISSN: 1465-993X
eISSN: 1465-9921
WOS ID: 000471978900002
Scopus EID: 2-s2.0-85067565122
PMID: 31208406
Embase PUI: L628143116
Share
Statistics
Item usage statisticsMetadata
Show Dublin Core item recordAuthor
Fernandez-Fabrellas, Estrella; Molina-Molina, Maria; Soriano, Joan B.; Rodriguez Portal, Jose Antonio; Ancochea, Julio; Valenzuela, Claudia; Xaubet, Antoni; Aburto Barrenetxea, M.; Alfageme Michavila, I; Bollo de Miguel, E.; Cano, E.; Casanova Espinosa, A.; Castillo Villegas, D.; Figuerola Mendal, J. A.; Garcia Sevila, R.; Gaudo Navarro, J., I; Gomez Carrera, L.; Gonzalez, J. M.; Herrera Lara, S.; Laporta Hernandez, R.; Marin Gonzalez, M.; Nieto Barbero, M. A.; Portillo, K.; Romero, A. D.; Sanchez Simon-Talero, R.; Sancho Chust, J. N.; Sellares Torres, J.; Soler Sempere, M. J.; Sauleda Roig, Jaume
Publication date
2019-06-17Document type
research articleCitation
Fernandez-Fabrellas E, Molina-Molina M, Soriano JB, Rodriguez Portal JA, Ancochea J, Valenzuela C, et al. Demographic and clinical profile of idiopathic pulmonary fibrosis patients in Spain: the SEPAR National Registry. Respir Res. 2019 Jun 17;20:127.Abstract
BackgroundLittle is known on the characteristics of patients diagnosed with idiopathic pulmonary fibrosis (IPF) in Spain. We aimed to characterize the demographic and clinical profile of IPF patients included in the IPF National Registry of the Spanish Respiratory Society (SEPAR).MethodsThis is a prospective, observational, multicentre and nationwide study that involved 608 IPF patients included in the SEPAR IPF Registry up to June 27th, 2017, and who received any treatment for their disease. IPF patients were predominantly males, ex-smokers, and aged in their 70s, similar to other registries.ResultsUpon inclusion, meanSD predicted forced vital capacity was 77.6%+/- 19.4, diffusing capacity for carbon monoxide was 48.5%+/- 17.7, and the 6-min walk distance was 423.5m +/- 110.4. The diagnosis was mainly established on results from the high-resolution computed tomography in the proper clinical context (55.0% of patients), while 21.2% of patients required invasive procedures (surgical lung biopsy) for definitive diagnosis. Anti-fibrotic treatment was prescribed in 69.4% of cases, 51.5% pirfenidone and 17.9% nintedanib, overall with a good safety profile.Conclusions The SEPAR IPF Registry should help to further characterize current characteristics and future trends of IPF patients in Spain and compare/pool them with other registries and cohorts.
Publisher version
https://dx.doi.org/10.1186/s12931-019-1084-0MeSH
Aged, 80 and overAged
Spain
Pyridones
Humans
Anti-Inflammatory Agents, Non-Steroidal
Middle Aged
Male
Prospective Studies
Female
Idiopathic Pulmonary Fibrosis
Societies, Medical
Registries
Retrospective Studies
DeCS
FemeninoSociedades Médicas
Masculino
Piridonas
Humanos
Persona de Mediana Edad
Estudios Prospectivos
Antiinflamatorios no Esteroideos
Anciano
Anciano de 80 o más Años
Estudios Retrospectivos
Fibrosis Pulmonar Idiopática
España
Sistema de Registros